Pharmaceutical groups Boehringer Ingelheim and Shire as well as Japanese conglomerate Mitsui’s corporate venturing unit and ATMI have helped Promethera Biosciences, a Belgium-based cell therapy company, raise €17m ($22.7m). The companies were joined in the series B round on Wednesday by Belgium-based venture capital firm SambrInvest. The Walloon Region, which has backed the company since…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
